# Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

> **NCT04651127** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sun Yat-sen University** · enrollment: 5 (actual)

## Conditions studied

- Cervical Cancer
- Cervix Cancer
- Cervix Neoplasm

## Interventions

- **DRUG:** Toripalimab + Chidamide

## Key facts

- **NCT ID:** NCT04651127
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-09
- **Primary completion:** 2023-01-26
- **Final completion:** 2023-01-26
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Five patients were enrolled in the study, but no treatment response was observed and all the patients had the best of response of prgressive disease. Given the lack of efficacy, the trial was terminated.
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04651127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04651127, "Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04651127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*